A rose by any other name
This article was originally published in Scrip
When Keryx Biopharmaceuticals gained FDA approval for ferric citrate, an iron-based treatment for dialysis patients with hyperphosphatemia last week, it emerged that the FDA had rescinded its original approval of the brand name Zerenex because of its similarity to another product’s name. The identity of the other product was not revealed, but an examination of the latest Orange List reveals a number of possible candidates, including Serevent, Xenazine, Zanaflex and Zorvolex. These names may look very similar in print, but on a hastily written prescription the possibility of confusion cannot be ruled out.
You may also be interested in...
The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.
Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.
The market for minimally invasive weight loss devices will reach more than $290 million by 2021, according to a new report from Informa’s Meddevicetracker. Issues relating to laparoscopic adjustable gastric banding systems will result in a greater emphasis being placed on intragastric balloons, which will grow at twice the segment average.